Compound News and Research

RSS

Scientists find high levels of previously unsuspected pollutant in homes, environment

Scientists at Indiana University found high levels of a previously unsuspected pollutant in homes, in an electronic waste recycling facility and in the natural environment. People are likely to be exposed to this pollutant by breathing contaminated dust or through skin contact.

30 Oct 2018

Promising potential of stimuli-responsive nanomaterial for cancer therapy

Nanosystems that deliver anticancer drugs or imaging materials to tumors are showing significant progress, particularly those that respond to tumor-related stimuli, according to a review published in the journal Science and Technology of Advanced Materials.

30 Oct 2018

Neuroene Therapeutics receives $1.5 million NIH grant to develop anti-seizure compound for epilepsy

Neuroene Therapeutics, a start-up company founded by mitochondrial biologist Sherine S. L. Chan, Ph.D. and medicinal chemist C. James Chou, Ph.D. of the Medical University of South Carolina, has received a $1.5 million NIH Phase II Small Business Innovation Research grant to optimize vitamin K analogues that could improve seizure control in patients with drug-resistant epilepsy.

29 Oct 2018

That’s a lot of scratch: The $48,329 allergy test

Janet Winston had a rash that wouldn't go away. The English professor from Eureka, Calif., always had been sensitive to ingredients in skin creams and cosmetics. This time, however, the antifungal cream she was prescribed to treat her persistent rash seemed to make things worse. Was she allergic to that, too?

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Novartis enters into clinical development agreement with Pfizer to improve treatment of NASH

Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).

29 Oct 2018

Active ingredient in magic mushrooms could soon become a depression treatment

The active ingredient in magic mushrooms is psilocybin. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushroom and is the reason behind the “high” provided by the magic mushrooms. Now, Psilocybin may soon achieve legal status to be used for treatment of difficult to treat depressive illness.

26 Oct 2018

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

Scientists at Nanyang Technological University, Singapore have engineered an antiviral peptide that exploits the Zika virus at its Achilles' heel - the viral membrane - hence stopping the virus from causing severe infections.

24 Oct 2018

Researchers examine complex causes of preterm and low-birthweight babies in India

Women in India who spend more time fetching water, use a shared latrine, and endure harassment from others are more apt to give birth to a pre-term or low-birthweight baby, according to a new study from the University of Iowa.

23 Oct 2018

New type of molecule shows early promise against treatment-resistant prostate cancer

A new type of molecule blocks the action of genes that drive the growth of therapy-resistant prostate cancer, a new study finds.

23 Oct 2018

Scientists develop new class of compounds for treatment of progressive neurodegenerative disorder

St. Jude Children's Research Hospital investigators have developed a new class of compounds that extended the lives and eased symptoms of mice with a progressive neurodegenerative human disorder.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Drug cocktail that increases lifespan discovered

A team of researchers led by Principal Investigator Dr Jan Gruber from Yale-NUS College has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Newly discovered compound shows potential for treating Parkinson's disease

A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease.

19 Oct 2018

Scripps researchers successfully test potential new smoking-cessation treatment in rodents

Scientists at Scripps Research have successfully tested a potential new smoking-cessation treatment in rodents.

19 Oct 2018

New urea sorbent could speed up the development of wearable artificial kidney

There just aren't enough kidney transplants available for the millions of people with renal failure.

19 Oct 2018

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.

17 Oct 2018

Age-related estrogen increase may be the culprit behind inguinal hernias in men

An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 in Proceedings of the National Academy of Sciences.

16 Oct 2018

Compound News and Research

Scientists find high levels of previously unsuspected pollutant in homes, environment

Promising potential of stimuli-responsive nanomaterial for cancer therapy

Neuroene Therapeutics receives $1.5 million NIH grant to develop anti-seizure compound for epilepsy

That’s a lot of scratch: The $48,329 allergy test

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Novartis enters into clinical development agreement with Pfizer to improve treatment of NASH

Active ingredient in magic mushrooms could soon become a depression treatment

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

Researchers examine complex causes of preterm and low-birthweight babies in India

New type of molecule shows early promise against treatment-resistant prostate cancer

Scientists develop new class of compounds for treatment of progressive neurodegenerative disorder

Study: Targeting specific genomic mutation in breast cancer improves survival

Drug cocktail that increases lifespan discovered

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Newly discovered compound shows potential for treating Parkinson's disease

Scripps researchers successfully test potential new smoking-cessation treatment in rodents

New urea sorbent could speed up the development of wearable artificial kidney

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Age-related estrogen increase may be the culprit behind inguinal hernias in men

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News